Boehringer Ingelheim and the Mary Tyler Moore Vision Initiative (MTM Vision) jointly announce the start of a long-term collaboration as Boehringer becomes the first pharmaceutical company to join the ...

AstraZeneca to invest $3.5 billion in R&D and manufacturing in US: Cambridge, UK Wednesday, November 13, 2024, 09:00 Hrs [IST] AstraZeneca, a global, science-led biopharmaceutical ...

The All India Organization of Chemists and Druggists (AIOCD) has recently expressed concern over the partnership between Swiggy Instamart and PharmEasy for a rapid drug delivery model in the country.

The National Accreditation Board for Testing and Calibration Laboratories (NABL), under the Quality Council of India (QCI), has announced a collaborative effort with Man-Made Textile Research ...

The Indian pharmaceutical industry is advocating for enhanced fire safety measures and improved insurance coverage for employees working in pharmaceutical facilities. Given the highly volatile and ...

An inter-ministerial committee formed by the Union health ministry has recommended amendments to the Food Safety and Standards Act, 2006 and regulations on nutraceuticals and health supplements, to ...

The centrally sponsored scheme for strengthening of medical devices industry (SMDI), launched by the Central government last week, was widely welcomed by the medical devices industry in the country.

Govt should roll out comprehensive National Cancer Care Policy with dedicated funding outlay: FICCI-EY Parthenon Report: Our ...

Oncoinvent announces positive interim results from phase 1/2a studies of Radspherin for treatment of peritoneal carcinomatosis: Oslo, Norway Tuesday, November 12, 2024, 18:00 Hrs ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, has announced it is pledging $7.8 million to the ‘Fund our Futures’ campaign led by ...

EnteroBiotix Limited, a clinical-stage biotechnology company focussed on developing best-in-class full-spectrum microbiome therapeutics, announced positive results from its phase 1b IMPuLCE study ...

Tectonic Therapeutic to present positive phase 1a results of TX45, a long-acting, Fc-relaxin fusion protein at AHA 2024: Watertown, Massachusetts Tuesday, November 12, 2024, 13:00 ...